Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Terumo Corporation
  6. Summary
    4543   JP3546800008

TERUMO CORPORATION

(4543)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
5116 5132 5103 5020 5050 Last
1533700 1088500 1382200 1462500 1640000 Volume
-0.95% +0.31% -0.57% -1.63% +0.60% Change
Estimated financial data (e)
Sales 2022 693 B 6 102 M 6 102 M
Net income 2022 98 507 M 868 M 868 M
Net Debt 2022 39 592 M 349 M 349 M
P/E ratio 2022 38,7x
Yield 2022 0,61%
Sales 2023 744 B 6 550 M 6 550 M
Net income 2023 110 B 969 M 969 M
Net cash position 2023 14 013 M 123 M 123 M
P/E ratio 2023 34,7x
Yield 2023 0,67%
Capitalization 3 818 B 33 576 M 33 637 M
EV / Sales 2022 5,57x
EV / Sales 2023 5,12x
Nbr of Employees 26 482
Free-Float 95,2%
More Financials
Company
TERUMO CORPORATION is a manufacturer of medical supplies. The Company operates in three segments. The Cardiac and Vascular Company segment is engaged in the manufacture of catheter system and cardiopulmonary system products, the import of the cardiopulmonary systems and artificial blood vessels, as well as the sale of products mainly to hospitals and clinics nationwide through agents. The Hospital Company segment is... 
More about the company
Ratings of Terumo Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about TERUMO CORPORATION
10/22TERUMO : Blood and Cell Technologies Opens Manufacturing Facility in Costa RicaThe company..
PU
10/14Japanese shares rise as tech stocks track Nasdaq peers higher
RE
10/13Nikkei jumps tracking Nasdaq, Tokyo Electron shines
RE
10/11Japan shares track Wall Street lower, tech down on U.S. rate hike fears
RE
10/07TERUMO : Blood and Cell Technologies is collaborating with BioCentriq to provide technolog..
PU
10/04TERUMO : Aortic Announces First Implant of Landmark Thoracoabdominal Hybrid Device
PU
09/29TERUMO CORPORATION : Ex-dividend day for interim dividend
FA
09/22TERUMO : Aortic Announces Launch of Landmark Global Surgical Graft Study
PU
09/21TERUMO : CVS Fully Exits Consent Decree
PU
09/21TERUMO : Celebrates 100-Year Anniversary in Asia with an Eye to the Future
PU
09/21TERUMO : India releases Special Postal Cover and My Stamp to Commemorate 100 years of Teru..
PU
09/17TERUMO : Aortic Announces First Commercial Implants of RelayPro Endovascular Device in the..
PU
09/14TERUMO : Blood and Cell Technologies announces a new software update for its Finia® Fill a..
PU
09/09TERUMO : Etiometry and Terumo Cardiovascular Announce Partnership to Deliver Enhanced Moni..
PU
08/30TERUMO : MASTER DAPT, a Landmark Trial on Abbreviated DAPT Post-implantation of Terumo's U..
PU
More news
News in other languages on TERUMO CORPORATION
07/01NIKKEI 225 : Borsa Tokyo in calo, nuovi contagi alimentano timori per lenta ripresa econom..
05/11MÄRKTE ASIEN/Talfahrt bei Technologiewerten - Inflationssorgen belasten
03/10PLANETA BOLSA : La revista de prensa del miércoles 10 de marzo 2021
03/10PLANÈTE BOURSE  : La revue de presse du mercredi 10 mars 2021
02/15Coronavirus/Japon-Une pénurie de seringue ralentit la vaccination
More news
Stock Trading Strategies
TERUMO CORPORATION - 09/02
Big comeback of buyers
BUY
More Stock Trading Analysis
Chart TERUMO CORPORATION
Duration : Period :
Terumo Corporation Technical Analysis Chart | 4543 | JP3546800008 | MarketScreener
Technical analysis trends TERUMO CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 5 050,00 JPY
Average target price 5 573,08 JPY
Spread / Average Target 10,4%
EPS Revisions
Managers and Directors
Shinjiro Sato President, CEO & Representative Director
Naoki Muto Chief Financial & Accounting Officer
Takayoshi Mimura Chairman
Katsuya Takeuchi Chief Information Officer & Executive Officer
Kazuhisa Senshu Chief Clinical & Regulatory Affairs Officer
Sector and Competitors
1st jan.Capi. (M$)
TERUMO CORPORATION17.12%33 576
ABBOTT LABORATORIES15.74%224 651
MEDTRONIC PLC5.08%165 656
BECTON, DICKINSON AND COMPANY-1.25%70 962
HOYA CORPORATION21.65%56 316
DEXCOM, INC.53.24%54 815